Blood Brothers No More: Hologic Unloads Blood-Screening Business To Partner Grifols
Executive Summary
Hologic's partner in the blood-screening business, Grifols SA, will buy-out Hologic's share for $1.85bn. Grifols already owns all the customer-facing parts of the business; it will now take on research, development and manufacture of assays and instruments based on nucleic acid testing for transfusion and transplantation screening.
You may also be interested in...
FDA Approves Roche Molecular Cobas Test As Zika Virus Blood Donor Screen
US FDA approved Roche Molecular Diagnostics' cobas Zika virus test to screen plasma specimens from blood and organ donors.
M&A Deals Analysis: February Sees Billion-Dollar Buys Bite
Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.
Hologic Stitches Medical Aesthetics Into Women's Health
Hologic is acquiring Cynosure for $1.65bn, saying medical aesthetics will complement its existing OB/GYN and women’s health businesses. It is the latest in a series of recent moves intended to accelerate Hologic’s growth.